BIP Wealth LLC Acquires 280 Shares of Eli Lilly and Company (NYSE:LLY)

BIP Wealth LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 45.5% during the 4th quarter, Holdings Channel reports. The firm owned 896 shares of the company’s stock after purchasing an additional 280 shares during the period. BIP Wealth LLC’s holdings in Eli Lilly and Company were worth $522,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of LLY. Lipe & Dalton bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $26,000. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Legacy Financial Group LLC bought a new position in Eli Lilly and Company during the 3rd quarter worth approximately $35,000. Optiver Holding B.V. bought a new position in Eli Lilly and Company during the 3rd quarter worth approximately $36,000. Finally, Family CFO Inc bought a new position in Eli Lilly and Company during the 3rd quarter worth approximately $40,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the sale, the insider now owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Performance

LLY stock traded down $7.48 during midday trading on Thursday, reaching $724.72. 1,698,612 shares of the company were exchanged, compared to its average volume of 3,021,339. The business has a 50-day moving average price of $763.40 and a two-hundred day moving average price of $664.52. The firm has a market capitalization of $688.60 billion, a price-to-earnings ratio of 124.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a one year low of $370.68 and a one year high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.09 earnings per share. Equities research analysts forecast that Eli Lilly and Company will post 12.52 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on LLY shares. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Citigroup lifted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday, April 15th. Finally, Bank of America lifted their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.